---

$52.45

+2.2400 ( +4.07% ) 331.7K

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-09-20	Buy	115.00	Heron Patrick J
2024-09-10	Buy	230.00	Heron Patrick J
2024-07-24	Sale	-34013.00	Peetz Christopher
2024-07-03	Sale	-1042.00	Howe Jolanda
2024-06-25	Sale	-30559.00	Vig Pamela
2024-06-07	Sale	-8779.00	Fischer Laurent
2024-06-07	Sale	-8779.00	Brege Laura
2024-06-07	Sale	-8779.00	Heron Patrick J
2024-06-07	Sale	-8779.00	GREY MICHAEL G
2024-06-07	Sale	-8779.00	Fairey William

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.